Fujisawa/Yamanouchi Merger Will Create "Astellas Pharma"; Deal On Track For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas is based on the Latin, Greek and English words for stars and is intended to sound like Japanese expression for "to shine on tomorrow." The companies will outline Astellas business strategies and financial targets by November.
You may also be interested in...
Fujisawa's Antifungal Mycamine Clears FDA
The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.
Fujisawa's Antifungal Mycamine Clears FDA
The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.
Yamanouchi Seeks Larger U.S. Presence Through Fujisawa Merger
The $7.8 bil. deal would ramp up the companies' sales efforts to primary care physicians. In the U.S., Fujisawa details only to the specialty care audience, while Yamanouchi relies on out-licensing agreements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: